Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 7/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15267699 | 0.85 | KMT2A (0.60) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL11638641 | 0.84 | SMN1; SMN2 (0.59) | MAPTALDH1A1NPC1SMN1; SMN2RAB9A | |
| SCHEMBL925339 | 0.82 | MAPT (0.64) | MAPTALDH1A1NPC1SMN1; SMN2MAPK1 | |
| SCHEMBL31570085 | 0.82 | MAPT (0.64) | MAPTALDH1A1NPC1SMN1; SMN2MAPK1 | |
| SCHEMBL7363709 | 0.82 | ALDH1A1 (0.66) | MAPTALDH1A1NPC1SMN1; SMN2MAPK1 | |
| SCHEMBL3911049 | 0.82 | CA12 (0.54) | ALDH1A1RAB9AMEN1KMT2APOLB | |
| SCHEMBL14000503 | 0.81 | GPR55 (0.56) | NPC1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL1245786 | 0.81 | MEN1 (0.77) | MAPTALDH1A1NPC1MAPK1RAB9A | |
| SCHEMBL10780544 | 0.81 | ALDH1A1 (0.56) | MAPTALDH1A1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL17475956 | 0.81 | MAPT (0.62) | MAPTALDH1A1NPC1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180783-B2 | Method for producing chiral amines | VITO NV (BE) | 2021-11-23 | — | — | US | claimed |
| EP-3676387-B1 | METHOD FOR PRODUCING CHIRAL AMINES | VITO NV (BE) | 2021-09-29 | — | — | EP | claimed |
| US-20210062233-A1 | METHOD FOR PRODUCING CHIRAL AMINES | VITO NV (BE) | 2021-03-04 | — | — | US | claimed |
| EP-3676387-A1 | METHOD FOR PRODUCING CHIRAL AMINES | Vito NV (BE) | 2020-07-08 | — | — | EP | claimed |
| WO-2019043186-A1 | METHOD FOR PRODUCING CHIRAL AMINES | VITO NV (BE) | 2019-03-07 | — | — | WO | claimed |
| US-11180783-B2 | Method for producing chiral amines | VITO NV (BE) | 2021-11-23 | — | — | US | disclosed |
| EP-3676387-B1 | METHOD FOR PRODUCING CHIRAL AMINES | VITO NV (BE) | 2021-09-29 | — | — | EP | disclosed |
| US-20210062233-A1 | METHOD FOR PRODUCING CHIRAL AMINES | VITO NV (BE) | 2021-03-04 | — | — | US | disclosed |
| EP-3676387-A1 | METHOD FOR PRODUCING CHIRAL AMINES | Vito NV (BE) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019043186-A1 | METHOD FOR PRODUCING CHIRAL AMINES | VITO NV (BE) | 2019-03-07 | — | — | WO | disclosed |
| US-20160074373-A1 | METHODS AND COMPOSITIONS FOR INHIBITING HUMAN COPPER TRAFFICKING PROTEINS ATOX1 AND CCS | THE UNIVERSITY OF CHICAGO (US) | 2016-03-17 | — | — | US | disclosed |
| US-6342503-B1 | ANTIDEPRESSANTS, EATING DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2002-01-29 | — | — | US | disclosed |
| US-6107301-A | PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0723533-A1 | 1N-ALKYL-N-ARYLPYRIMIDINAMINES AND DERIVATIVES THEREOF | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995010506-A1 | 1N-ALKYL-N-ARYLPYRIMIDINAMINES AND DERIVATIVES THEREOF | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074373-A1 | METHODS AND COMPOSITIONS FOR INHIBITING HUMAN COPPER TRAFFICKING PROTEINS ATOX1 AND CCS | CLINT1, QSOX1, ACOX1 | MAPT 3330/4885ALDH1A1 725/4885NPC1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.